Navigation Links
Kite Pharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Date:1/7/2014

LOS ANGELES, Jan. 7, 2014 /PRNewswire/ -- Kite Pharma today announced that Dr. Arie Belldegrun, Executive Chairman and Founder of Kite Pharma, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014, at 1:30 p.m. Pacific Time.  The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.

(Logo:  http://photos.prnewswire.com/prnh/20130513/MM13332LOGO )

About Kite Pharma

Kite Pharma, Inc. (Kite) is a privately held development stage biotechnology company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch, Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR and TCR products, directed to a wide range of cancer indications. These novel personalized and targeted immunotherapies, which capitalize on the selectivity and potency of immune cells, are designed to provide significant and durable clinical benefit regardless of tumor origin, disease stage, and prior treatments. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing cutting-edge immunotherapies and oncology treatments. Kite is based in Los Angeles, CA.  For more information, visit the company's website at http://www.kitepharma.com.

Kite Contact:
Dr. Arie Belldegrun
Chief Executive Officer & Executive Chairman
(310) 824-9999

For Media:
Justin Jackson
Burns McClellan
(212) 213-0006
jjackson@burnsmc.com

For Investors:
Caitlyn Murphy
Burns McClellan
(212) 213-0006
cmurphy@burnsmc.com


'/>"/>
SOURCE Kite Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Updates, Notices, Quarterly Reports, and Revenue Guidance Updates - Research Report on NPS Pharmaceuticals, Oramed, PAREXEL, PhotoMedex, and Cell Therapeutics
2. Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
3. Velocity Pharmaceutical Development Announces Appointment of Stuart Sedlack as Senior Vice President, Business Development
4. Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 13
5. Ralphs Pharmacies Providing Prescriptions at No Upfront Cost for Customers Enrolled in the Public Health Insurance Marketplace
6. CVS/pharmacy Helps Customers Kick Off a Healthy New Year with Online Vitamin Resources and Huge Savings
7. Avanir Pharmaceuticals to Present at J.P. Morgan 32nd Annual Healthcare Conference
8. ANI Pharmaceuticals Enters Development Agreement for Generic Drug Product with Sterling Pharmaceutical Services
9. Arena Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
10. Isis Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
11. Inovio Pharmaceuticals to Present at Biotech Showcase 2014 Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
Breaking Medicine News(10 mins):